Compare Crispr Therapeutics AG (CRSP) vs Monster Beverage Corp (MNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Monster Beverage Corp — how do they compare? Crispr Therapeutics AG trades at $51.39 (market cap $4.97B), while Monster Beverage Corp trades at $98.18 (market cap $95.85B). The key difference: Monster Beverage Corp is far larger — about 19.3× Crispr Therapeutics AG's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | MNST | |
|---|---|---|
Market Cap | $4.97B | $95.85B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $98.01 |
52-Week Low | $44.34 | $58.65 |
Enterprise Value | $3.32B | $94.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Monster Beverage (MNST) trades at $97.07, down 0.33% on the day, with strong technical bullish signals from moving averages and a neutral RSI. The company demonstrates robust fundamentals with 2025 revenue of $8.29B, net income of $1.91B, and consistent earnings beats. Recent corporate actions include a 2-for-1 stock split effective August 11, 2026, reflecting management confidence in continued growth prospects.
MNST presents a compelling growth story with accelerating international expansion and product innovation driving market share gains. However, premium valuation multiples (P/E 46.89, P/S 10.89) create vulnerability to earnings disappointments. Analyst consensus remains positive with 53% buy ratings, though the $94.60 price target suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →
